Educational Notice
Peptidings provides information for educational and research purposes only. The peptides discussed on this page are subjects of ongoing scientific research. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Sexual Health & Low Libido
This category contains one of the clearest regulatory success stories in the peptide space. PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women—one of the few peptides approved specifically for a sexual health indication. The other compounds here operate through distinct mechanisms: hypothalamic reproductive signaling, central oxytocin pathways, and GnRH receptor agonism. Evidence quality varies substantially, and the distinction between approved therapeutic use and self-experimentation context matters considerably in this category.
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only
It’s Complicated
Compounds with Research Relevant to Sexual Health and Low Libido
Each compound links to its full pillar article. The most useful sections for evaluating a specific application are the Claims vs. Evidence table and the Safety, Risks, and Limitations section. Evidence tiers reflect the strongest available data for a compound overall—not necessarily for this specific application.
Leuprolide: What the Research Actually Shows
FDA-approved GnRH agonist that paradoxically suppresses sex hormones through continuous receptor desensitization. Standard of care for prostate cancer ADT, endometriosis, uterine fibroids, and central precocious puberty. Cross-cluster compound covering both Sexual Health and Oncology applications.
Read the research →
Melanotan II: What the Research Actually Shows
Melanotan II activates MC1R for tanning and MC3R/MC4R for libido — the same receptors as PT-141. The accidental discovery story, the receptor map, and the safety profile that matters.
Read the research →
PT-141 (Bremelanotide): What the Research Actually Shows
The only FDA-approved peptide specifically for sexual dysfunction — bremelanotide activates MC3R and MC4R in the hypothalamus to generate sexual desire centrally, bypassing the vascular mechanism entirely. Approved for HSDD in premenopausal women; off-label in men via compounding.
Read the research →
Guides Relevant to This Condition
How to Reconstitute Lyophilized Peptides
Bacteriostatic water, reconstitution ratios, vial handling
FDA Regulatory Explainer
Category 1, 2, and 3 compounds—what the classifications mean for research use
Peptide Injection Technique Guide
Subcutaneous and intramuscular injection, site rotation, safety
Research Cluster
These compounds are covered in depth in the Sexual Health and Hormonal Peptides cluster hub.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.